AbbVie Inc. (ABBV) P/E Ratio History
ExpensiveTrading at 111.9x vs 5Y avg 58.7x · 95th percentile · Material premium to history · Data 2012–2026
Loading P/E history...
P/E Ratio Analysis
As of September 24, 2026, AbbVie Inc. (ABBV) trades at a price-to-earnings ratio of 111.9x, with a stock price of $265.32 and trailing twelve-month earnings per share of $3.57.
The current P/E is 91% above its 5-year average of 58.7x. Over the past five years, ABBV's P/E has ranged from a low of 17.8x to a high of 173.9x, placing the current valuation at the 95th percentile of its historical range.
Compared to the Healthcare sector median P/E of 24.0x, ABBV trades at a 367% premium to its sector peers. The sector includes 225 companies with P/E ratios ranging from 0.0x to 174.5x.
Relative to the broader market, ABBV commands a significant premium over the S&P 500 median P/E of 25.5x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ABBV DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ABBV Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
ABBV P/E vs Peers
Specialty and biologics-focused pharma peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $648B | 24.4 | 1.64 | +91% | |
| $373B | 20.7 | 0.98 | +8% | |
| $159B | 20.5 | - | -4% | |
| $127B | 18.0 | - | +178% | |
| $1.1T | 51.0 | 1.77 | +96% | |
| $221B | 28.8 | 9.80 | +88% | |
| $190B | 22.5 | 0.17Best | +1684%Best | |
| $33B | 25.5 | - | -21% | |
| $83B | 19.4 | 3.06 | +8% | |
| $102B | 11.6Lowest | - | +46% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
ABBV Historical P/E Data (2012–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Period End | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q2 | - | $251.64 | $3.55 | 70.9x | +91% |
| FY2026 Q1 | - | $217.49 | $2.04 | 106.6x | +188% |
| FY2025 Q4 | Dec 31 2025 | $228.49 | $2.37 | 96.4x | +160% |
| FY2025 Q3 | - | $231.54 | $1.33 | 173.9x | +369% |
| FY2025 Q2 | Jun 30 2025 | $185.62 | $2.11 | 87.9x | +137% |
| FY2025 Q1 | Mar 31 2025 | $209.52 | $2.35 | 89.1x | +140% |
| FY2024 Q4 | - | $177.70 | $2.40 | 74.0x | +100% |
| FY2024 Q3 | Sep 30 2024 | $197.48 | $2.88 | 68.6x | +85% |
| FY2024 Q2 | Jun 30 2024 | $171.52 | $3.00 | 57.2x | +54% |
| FY2024 Q1 | Mar 31 2024 | $182.10 | $3.37 | 54.0x | +46% |
| FY2023 Q4 | Dec 31 2023 | $154.97 | $2.73 | 56.8x | +53% |
| FY2023 Q3 | Sep 30 2023 | $149.06 | $3.66 | 40.7x | +10% |
| FY2023 Q2 | Jun 30 2023 | $134.73 | $4.88 | 27.6x | -25% |
| FY2023 Q1 | Mar 31 2023 | $159.37 | $4.25 | 37.5x | +1% |
| FY2022 Q4 | Dec 31 2022 | $161.61 | $6.65 | 24.3x | -34% |
| FY2022 Q3 | Sep 30 2022 | $134.21 | $7.52 | 17.8x | -52% |
| FY2022 Q2 | - | $153.16 | $7.08 | 21.6x | -42% |
| FY2022 Q1 | - | $162.11 | $6.99 | 23.2x | -37% |
| FY2021 Q4 | Dec 31 2021 | $135.40 | $6.45 | 21.0x | -43% |
| FY2021 Q3 | - | $107.87 | $4.20 | 25.7x | -31% |
| FY2021 Q2 | Jun 30 2021 | $112.64 | $3.71 | 30.4x | -18% |
| FY2021 Q1 | Mar 31 2021 | $108.22 | $2.84 | 38.1x | +3% |
| FY2020 Q4 | - | $107.15 | $2.87 | 37.3x | +1% |
| FY2020 Q3 | Sep 30 2020 | $87.59 | $4.74 | 18.5x | -50% |
| FY2020 Q2 | - | $98.18 | $4.71 | 20.8x | -44% |
| FY2020 Q1 | - | $76.19 | $5.65 | 13.5x | -64% |
| FY2019 Q4 | - | $88.54 | $5.28 | 16.8x | -55% |
| FY2019 Q3 | Sep 30 2019 | $75.72 | $2.18 | 34.7x | -6% |
| FY2019 Q2 | Jun 30 2019 | $72.72 | $2.73 | 26.6x | -28% |
| FY2019 Q1 | Mar 31 2019 | $80.59 | $3.50 | 23.0x | -38% |
| FY2018 Q4 | Dec 31 2018 | $92.19 | $3.59 | 25.7x | -31% |
| FY2018 Q3 | Sep 30 2018 | $94.58 | $4.84 | 19.5x | -47% |
| FY2018 Q2 | Jun 30 2018 | $92.65 | $4.04 | 22.9x | -38% |
| FY2018 Q1 | Mar 31 2018 | $94.65 | $3.97 | 23.8x | -36% |
| FY2017 Q4 | Dec 31 2017 | $96.71 | $3.29 | 29.4x | -21% |
| FY2017 Q3 | Sep 30 2017 | $88.86 | $4.11 | 21.6x | -42% |
| FY2017 Q2 | Jun 30 2017 | $72.51 | $4.07 | 17.8x | -52% |
| FY2017 Q1 | Mar 31 2017 | $65.16 | $3.86 | 16.9x | -54% |
| FY2016 Q4 | Dec 31 2016 | $62.62 | $3.63 | 17.3x | -53% |
| FY2016 Q3 | Sep 30 2016 | $63.07 | $3.70 | 17.0x | -54% |
| FY2016 Q2 | - | $61.91 | $3.47 | 17.8x | -52% |
| FY2016 Q1 | - | $57.12 | $3.32 | 17.2x | -54% |
| FY2015 Q4 | - | $59.24 | $3.12 | 19.0x | -49% |
| FY2015 Q3 | Sep 30 2015 | $54.41 | $1.69 | 32.2x | -13% |
| FY2015 Q2 | - | $67.19 | $1.26 | 53.3x | +44% |
| FY2015 Q1 | - | $58.54 | $1.11 | 52.7x | +42% |
| FY2014 Q4 | Dec 31 2014 | $65.44 | $1.09 | 60.0x | +62% |
| FY2014 Q3 | - | $57.76 | $2.30 | 25.1x | -32% |
| FY2014 Q2 | Jun 30 2014 | $56.44 | $2.59 | 21.8x | -41% |
| FY2014 Q1 | Mar 31 2014 | $51.40 | $2.57 | 20.0x | -46% |
| FY2013 Q4 | - | $52.81 | $2.56 | 20.6x | -44% |
| FY2013 Q3 | Sep 30 2013 | $44.73 | $2.82 | 15.9x | -57% |
| FY2013 Q2 | Jun 30 2013 | $41.34 | $3.22 | 12.8x | -65% |
| FY2013 Q1 | Mar 31 2013 | $40.78 | $3.34 | 12.2x | -67% |
| FY2012 Q4 | Dec 31 2012 | $34.16 | $3.28 | 10.4x | -72% |
Average P/E for displayed period: 37.1x
ABBV Chart Terminal
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
Live Breakouts Feed
High-probability breakout stocks crossing their pivot across 5 pattern engines.
ABBV Stock Analysis
Bull/bear thesis, analyst target revisions, and earnings execution.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
14+ years return with dividends reinvested.
Peer Comparison
Compare growth, multiples, and margins vs sector.
ABBV — Frequently Asked Questions
Quick answers to the most common questions about buying ABBV stock.
What is ABBV's P/E ratio?
AbbVie Inc. (ABBV) trailing twelve-month P/E ratio is 111.9x, based on TTM diluted EPS of $3.57. The 5-year average P/E is 58.7x and the historical range spans 17.8x to 173.9x.
Is ABBV stock overvalued or undervalued?
ABBV trades at 111.9x P/E, above its 5-year average of 58.7x. The 95th percentile ranking within the 17.8x–173.9x historical range indicates a premium to historical valuation.
Is ABBV stock expensive?
Yes, ABBV is expensive relative to its own history. The current P/E of 111.9x is above the 5-year average of 58.7x and also above the Healthcare sector median of 24.0x. The stock sits at the 95th percentile of its 5-year valuation range.
What is ABBV's historical P/E range?
Over the past 5 years, ABBV's P/E ratio has ranged from 17.8x to 173.9x, with a median of 56.8x and an average of 58.7x. The current P/E of 111.9x places the stock at the 95th percentile of this range. Full historical data spans 2012–2026.
How does ABBV's P/E compare to the S&P 500?
ABBV trades at 111.9x P/E versus the S&P 500 median of 25.5x. The 339% premium to the market typically reflects higher expected earnings growth or quality.
How does ABBV's valuation compare to Healthcare peers?
AbbVie Inc. P/E of 111.9x compares to the Healthcare sector median of 24.0x. The premium reflects expected growth above peers or stronger fundamentals. See the peer comparison table on this page for ticker-by-ticker P/E and PEG.
What is ABBV's PEG ratio?
ABBV PEG ratio is N/A, based on a P/E of 111.9x and EPS growth of -0.8%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is ABBV's earnings yield?
ABBV earnings yield is 0.89%, the inverse of its 111.9x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.